BioArctic (Buy, TP: SEK206.00) - An antibody is not an antibody…
BioArctic presented data that strengthens our positive view of BAN2401. Since the termination of aducanumab and crenezumab in H1 2019, there has been a lot of scepticism towards antibodies targeting amyloid-β. BioArctic presented comparative data on how strong BAN2401 binds to the neurotoxic species of amyloid-β and compared it with aducanumab. The company showed in vitro that BAN2401 binds up to 100x stronger to amyloid-β protofibrils than aducanumab. We believe this is an important differentiating factor that sets BAN2401 apart from other antibodies. We maintain our BUY and SEK206 target price on BioArctic.BioArctic is a research-based biopharma company which is engaged in developing new innovative disease modifying treatments based in antibodies (immunotheraphy) for neurodegenerative disease (i.e. diseases where the nervous system degenerates) such as Alzheimer's disease and Parkinson's disease and a treatment concept for complete spinal cord injuries (i.e. an injury where the spinal cord is completely broken). Co.'s operations are focused on research and development of new drugs for diseases and conditions with great medical need.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.